

NEUROCRINE BIOSCIENCES INC  
 Form 4  
 June 24, 2013

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Bozgian Haig P.

2. Issuer Name and Ticker or Trading Symbol  
 NEUROCRINE BIOSCIENCES INC [NBIX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 06/20/2013

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
 Chief Development Officer

NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

SAN DIEGO, CA 92130

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |   |
| Common Stock                    | 06/20/2013                           |  | S <sup>(2)</sup>               | 20,000  | D   | \$ 12.3 <sub>(3)</sub>                                   | 76,954 D  |
| Common Stock                    | 06/20/2013                           |  | S <sup>(2)</sup>               | 769   | D   | \$ 12.55 <sub>(4)</sub>                                  | 76,954 D  |
| Common Stock                    | 06/21/2013                           |  | S <sup>(2)</sup>               | 20,000  | D   | \$ 12.68 <sub>(5)</sub>                                  | 76,954 D  |
| Common Stock                    | 06/21/2013                           |  | S <sup>(2)</sup>               | 3,462   | D   | \$ 12.5 <sub>(6)</sub>                                   | 76,954 D  |

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Common Stock      06/21/2013      S<sup>(2)</sup>      500      D      \$ 13<sup>(7)</sup>      76,954      D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**      SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Nonstatutory Stock Option                  | \$ 2.59  | 06/20/2013                           |  | X <sup>(1)</sup>               | 20,000  | 10/11/2010 05/11/2017                                    | Common Stock  | 20,000                     |
| Nonstatutory Stock Option                  | \$ 2.59  | 06/21/2013                           |  | X <sup>(1)</sup>               | 20,000  | 10/11/2010 05/11/2017                                    | Common Stock  | 20,000                     |
| Incentive Stock Option                     | \$ 5.12  | 06/20/2013                           |  | X <sup>(1)</sup>               | 769   | 02/27/2009 02/27/2015                                    | Common Stock Option   | 769                        |
| Incentive Stock Option                     | \$ 5.12  | 06/20/2013                           |  | X <sup>(1)</sup>               | 3,462   | 02/27/2009 02/27/2015                                    | Common Stock  | 3,462                      |
| Nonstatutory Stock Option                  | \$ 10.9  | 06/20/2013                           |  | X <sup>(1)</sup>               | 500   | 09/26/2007 09/26/2013                                    | Common Stock  | 500                        |

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Bozigian Haig P.  
NEUROCRINE BIOSCIENCES, INC.  
12780 EL CAMINO REAL  
SAN DIEGO, CA 92130

Chief Development Officer

## Signatures

Margaret E. Valeur-Jensen, By Power of  
Attorney

06/24/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercise of in-the-money- or at-the-money derivative security

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.12 to \$12.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.51 to \$12.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.50 to \$12.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.50 to \$12.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.00 to \$13.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.